The latter one which included 4 trials (43,456 patients) suggested that GLP-1 RAs reduced MACE by 13% (HR 0.87, 95% CI 0.820.93), an effect which was consistent in both subgroups (HR 0.91, 95% CI 0.850.97 and HR 0.80, 95% CI 0.720.90 with and without metformin, respectively)
Nooms philosophy is that sustainable results come from coupling pharmacotherapy with behavior change , in accordance with FDA guidance
If the problem is desire rather than mechanics, brain-acting peptides are the appropriate tool
Semaglutide and tirzepatide products have different indications, dosing schedules, contraindications, warnings, and side-effect profiles